CONSORTIUM THERAPEUTIC STUDIES OF PRIMARY CENTRAL NERVI*

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。加州大学洛杉矶分校神经肿瘤学项目将作为“成员机构”参加北美脑瘤联合会(NABTC)的临床试验。NABTC的成员机构还将包括威斯康星大学、匹兹堡大学、达纳·法伯癌症中心、M·D·安德森癌症中心、国家卫生研究院神经肿瘤学分院、加州大学旧金山分校、纪念斯隆·凯特琳癌症中心和德克萨斯大学圣安东尼奥分校的药代动力学中心。加州大学旧金山分校将担任NABTC的牵头机构，普拉多斯博士将担任小组组长。这笔赠款的重点将是对治疗成人原发性中枢神经系统恶性肿瘤，特别是多形性胶质母细胞瘤和其他高级别胶质瘤的有前景的新治疗剂或方法进行第一和第二阶段的临床评估。此外，我们还将进行具有潜在临床意义的中枢神经系统肿瘤生物学方面的辅助实验室研究。加州大学洛杉矶分校将继续扩展其与NABTC正在进行的工作，与该联盟的其他成员和NCI以协调一致的方式互动，以构思、创建和评估治疗中枢神经系统肿瘤的新方法。这在很大程度上将通过加州大学洛杉矶分校现有的环境和专业知识实现，包括医生调查人员、多学科方法、数据管理资源、患者群体、神经成像、手术和辐射以及药物控制程序的专业知识和先进仪器。加州大学洛杉矶分校还将为多机构礼仪概念的制定和礼仪行为提供有效的环境和专业知识。最后，加州大学洛杉矶分校拥有重要的基础设施专业知识，以帮助该财团满足对加速脑癌翻译研究至关重要的需求。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. UCLA Neuro-Oncology Program will participate in the clinical trials of the North American Brain Tumor Consortium (NABTC) as a "Member Institution". Member Institutions of the NABTC will also include, the University of Wisconsin, the University of Pittsburgh, Dana Farber Cancer Center, M D Anderson Cancer Center, the Neuro-Oncology Branch at the National Institutes of Health, the University of California, San Francisco, Memorial Sloan Kettering Cancer Center and the Pharmacokinetics Center at the University of Texas San Antonio. UCSF will be the Lead Institution and Dr. Prados the Group Leader for the NABTC. The focus of this grant will be to perform phase I and II clinical evaluations of promising new therapeutic agents or approaches for the treatment of primary CNS malignancies in adult patients, especially glioblastoma multiforme and other high grade gliomas. Additionally, we will perform ancillary laboratory studies of aspects of CNS tumor biology with potential clinical implications. UCLA will continue to extend it ongoing work with NABTC by interacting with other members of the consortium and with NCI in a concerted way to conceive, create and evaluate new approaches to the therapy of CNS tumors. This will be largely achieved through the existing environment and expertise that exist at UCLA including physician investigators, multidisciplinary approach, data management resources, patient population, expertise and advanced instrumentation for neuroimaging, surgery and radiation, and drug control procedures. UCLA will also provide an effective environment and expertise for multi-institutional protocol concept development and protocol conduct. Finally, significant infrastructure expertise exists at UCLA to aide the consortium with needs that are important for the acceleration of brain cancer translational research.